Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland.
about
Therapeutic monoclonal antibodies and clinical laboratory tests: When, why, and what is expected?Pediatric Pulmonology year in review 2015: Part 1.Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.Viruses in cystic fibrosis patients' airways.Cystic fibrosis year in review 2016.Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus.Alternative Viewpoint: Efficacy and Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis in Children with Cystic Fibrosis - An Unsolved Question with More to Be Asked.
P2860
Q38623790-F7939D37-6C31-4898-A886-DF1026F767ECQ38819881-A5AC5186-A200-4309-BB56-0587FF49FE40Q38830272-90EEDA29-E606-45D8-AF1D-6CE8DBAE0ACCQ39199043-C5A1D48E-BBD4-4166-A2EF-D4C894E1691CQ39368904-6F47CE89-3637-41C3-86F1-89B016058E26Q40199804-D442572D-9961-4996-BAA2-243AF305CE8AQ41929955-6B78A8FA-7499-48A2-8A06-51AB7C3206A5
P2860
Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Efficacy and long-term outcome ...... fibrosis in Northern Ireland.
@en
type
label
Efficacy and long-term outcome ...... fibrosis in Northern Ireland.
@en
prefLabel
Efficacy and long-term outcome ...... fibrosis in Northern Ireland.
@en
P2093
P2860
P356
P1476
Efficacy and long-term outcome ...... c fibrosis in Northern Ireland
@en
P2093
P2860
P304
P356
10.1002/PPUL.23376
P50
P577
2016-01-25T00:00:00Z